
BioPharm International Sponsored eBooks-09-15-2021
Biopharmaceutical companies are tasked with doing more with less while moving promising biotherapeutics into the clinic as fast as safely possible. Advances in High-Throughput Upstream Process Development takes a deep dive into an approach that addresses this challenge: combining definitive screening designs with advanced machine learning for accelerated drug development. Explore:
- Phase appropriate DOE strategies to minimize development timelines and maximize product life-cycle efficiency
- Efficient sample transfer from bioreactor to analytical platform
- Organizational strategies for data management from research to GMP production

Advertisement
Advertisement
Trending on BioPharm International
1
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
2
Evotec, BMS Gain Second FDA IND Acceptance for Molecular Glue Degrader
3
Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer
4
FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis
5
